好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Feasibility and Tolerability of Performing Portable MRI for Neurological Disorders in an Outpatient Neurology Clinic: A Prospective Cohort
General Neurology
S39 - General Neurology 2 (11:15 AM-11:27 AM)
001
To evaluate the feasibility, tolerability, and acceptability of portable brain magnetic resonance imaging (pMRI) among patients with neurological disorders.

Access to brain MRI can be challenging, especially for underserved patients, which may lead to disparities in neurological diagnosis and subsequent treatment.

This mixed methods study enrolled adults with one of four neurological disorders: mild cognitive impairment or dementia of the Alzheimer type, multiple sclerosis (MS), Parkinson disease (PD), or stroke. Participants were enrolled at the Massachusetts General Hospital outpatient clinic (01/2021-08/2025) and underwent a point-of-care, low-field portable MRI using a 0.064 Tesla scanner (Hyperfine) performed by trained non-physician research staff, along with pre- and post-scan surveys. For comparison, all participants received a standard brain MRI (1.5 Tesla). The Barriers to Care Scale, originally developed for people with HIV, was modified to assess challenges unique to individuals with neurological disorders.

Of 130 participants (53% male, 46% female), the mean age was 60.6 years (standard deviation (SD)=17.5). 71% reported at least one barrier to MRI care. The median interval between pMRI and standard MRI brain imaging was 48.5 days (IQR 113-26). Participants rated pMRI as tolerable, with 93% reporting comfort scores ≥7 (on a 10-point scale), and 78% indicating willingness to undergo future pMRI. Mean comfort ratings were significantly higher for pMRI (8.4) compared to traditional MRI (7.5; p<0.05), though the effect size was moderate (η²=0.096). No differences in tolerability or comfort were observed across disease, age, or sex groups. Common barriers to standard MRI access included transportation, cost, and scheduling, particularly among low-income or unemployed participants. Qualitative feedback emphasized the need for better physical positioning in the scanner but broadly supported the acceptability and potential uses of pMRI.

These findings broadly support the feasibility, tolerability, and patient acceptability of implementing pMRI in outpatient settings for people with neurological disorders.

Authors/Disclosures
Nomin Enkhtsetseg
PRESENTER
Ms. Enkhtsetseg has nothing to disclose.
Maya Mastick Ms. Mastick has nothing to disclose.
Joseph Sadok Mr. Sadok has nothing to disclose.
Matheus M. Mochetti Mr. Mochetti has nothing to disclose.
Annabel Sorby-Adams (Massachusetts General Hospital and Harvard Medical School) Annabel Sorby-Adams has nothing to disclose.
Lixin Guo Prof. Guo has nothing to disclose.
Cristina Trapaga Hacker Miss Trapaga Hacker has nothing to disclose.
Isabella Gomez Hjerthen No disclosure on file
Seungwon Lee, BA Miss Lee has nothing to disclose.
Siddharth Satish, Student Mr. Satish has nothing to disclose.
Andrew Siyoon Ham Andrew Siyoon Ham has nothing to disclose.
Justin B. Hill, Student Mr. Hill has nothing to disclose.
Denis T. Balaban, MD (Massachusetts General Hospital) Dr. Balaban has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Infucare. The institution of Dr. Balaban has received research support from ArgenX.
Kevin J. Kyle, MD (Massachusetts General Hospital) Dr. Kyle has nothing to disclose.
Rebecca L. Gillani, MD (Massachusetts General Hospital) The institution of Dr. Gillani has received research support from The Phyllis and Jerome Lyle Rappaport Foundation. The institution of Dr. Gillani has received research support from McCourt Foundation . The institution of Dr. Gillani has received research support from Roche.
Marcelo Matiello, MD, FAAN (Massachusetts General Hospital, Brigham, Harvard) Dr. Matiello has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Matiello has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Matiello has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for WoltersKluwer.
Aleksandar Videnovic, MD, MSc, FAAN (MGH Neurological Clinical Research Institute) Dr. Videnovic has nothing to disclose.
Eric Klawiter, MD, FAAN (Massachusetts General Hospital) Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Galen/Atlantica. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Banner Life Sciences. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Greenwich Biosciences. Dr. Klawiter has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for OM1. Dr. Klawiter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Klawiter has received research support from Biogen. The institution of Dr. Klawiter has received research support from Abbvie. The institution of Dr. Klawiter has received research support from Genentech.
W. T. Kimberly, MD, PhD (Massachusetts General Hospital) Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrocyte Pharmaceuticals. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acasti Pharma. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Kimberly has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Stryker. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics. Dr. Kimberly has stock in Woolsey Pharmaceuticals. Dr. Kimberly has stock in Acasti Pharma. The institution of Dr. Kimberly has received research support from NIH. The institution of Dr. Kimberly has received research support from Hyperfine, Inc.. The institution of Dr. Kimberly has received research support from Alzheimer's Association. Dr. Kimberly has received intellectual property interests from a discovery or technology relating to health care.
Farrah J. Mateen, MD, PhD, FAAN (Northwestern University Department of Neurology) Dr. Mateen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Mateen has received research support from Genentech. The institution of Dr. Mateen has received research support from Amgen. The institution of Dr. Mateen has received research support from TG Therapeutics. Dr. Mateen has received intellectual property interests from a discovery or technology relating to health care.